• Creative Medical Technology Holdings reported results from a pilot study of Ultrasome, a cell-free regenerative therapy for knee osteoarthritis.
• Results have already been presented, showing most patients experienced clinically meaningful improvements in mobility and pain, with no serious safety issues reported.
• Ultrasome is derived from GMP-produced CELZ-201 (Olastrocel), linking the program to CELZ-201, which is being evaluated in the FDA-cleared ADAPT clinical trial.
• Management positioned the cell-free approach as a path to scalable, off-the-shelf manufacturing aimed at broader outpatient use in a large osteoarthritis market.
• Next steps include expanding clinical execution of the Ultrasome program while evaluating commercialization and partnership options.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Creative Medical Technology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604280901PRIMZONEFULLFEED9707926) on April 28, 2026, and is solely responsible for the information contained therein.